Arcellx, Inc. (ACLX)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
115.01 USD
+0.01
(0.009%)
⇧
(April 21, 2026, 10:46 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 6:34 p.m. EDT
The $7.8 billion Gilead acquisition offer effectively transforms Arcellx into a cash-rich shell trading at a ~0.5x implied reversal discount to the $75-$82 strike range, but the stock is already down the equivalent of the $115 bid/ask spread relative to that floor. With no intrinsic growth story remaining (revenue collapsing), no dividend capability, and looming earnings uncertainty, holding the stock offers no alpha; the play is strictly to sell near the current price to realize the spread before the deal closes. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.367926 |
| AutoETS | 0.369047 |
| AutoARIMA | 0.369160 |
| AutoTheta | 0.461996 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 7.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | -1.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.904 |
| Revenue per Share | 0.396 |
| Market Cap | 6,725,763,072 |
| Forward P/E | -66.39 |
| Beta | 0.25 |
| Website | https://www.arcellx.com |
As of April 19, 2026, 6:34 p.m. EDT: Options flow shows distinct bearish positioning with heavy volume (310 lots) and Open Interest (5.4k) concentrated in OTM puts at strikes halfway down ($75) and near current price ($110). In contrast, call volume is negligible (649 total), heavily concentrated only in ITM positions. This confirms a hedge-heavy environment where market participants are protecting downside capital rather than anticipating a near-term upside breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8219265 |
| Address1 | 800 Bridge Parkway |
| All Time High | 115.13 |
| All Time Low | 6.035 |
| Ask | 147.32 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 606,160 |
| Average Daily Volume3 Month | 2,180,981 |
| Average Volume | 2,180,981 |
| Average Volume10Days | 606,160 |
| Beta | 0.248 |
| Bid | 82.81 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 6.946 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 115.01 |
| Current Ratio | 4.435 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 115.07 |
| Day Low | 115.005 |
| Debt To Equity | 12.904 |
| Display Name | Arcellx |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -246,404,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -25.676 |
| Enterprise To Revenue | 283.89 |
| Enterprise Value | 6,326,763,520 |
| Eps Current Year | -4.19552 |
| Eps Forward | -1.73223 |
| Eps Trailing Twelve Months | -4.07 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 105.231 |
| Fifty Day Average Change | 9.778999 |
| Fifty Day Average Change Percent | 0.09292888 |
| Fifty Two Week Change Percent | 82.19265 |
| Fifty Two Week High | 115.13 |
| Fifty Two Week High Change | -0.11999512 |
| Fifty Two Week High Change Percent | -0.0010422576 |
| Fifty Two Week Low | 47.86 |
| Fifty Two Week Low Change | 67.15 |
| Fifty Two Week Low Change Percent | 1.4030505 |
| Fifty Two Week Range | 47.86 - 115.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,643,985,000,000 |
| Float Shares | 42,251,664 |
| Forward Eps | -1.73223 |
| Forward P E | -66.39419 |
| Free Cashflow | -97,093,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 209 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -135,324,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12916 |
| Held Percent Institutions | 0.89972 |
| Implied Shares Outstanding | 58,479,812 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-02-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Arcellx, Inc. |
| Market | us_market |
| Market Cap | 6,725,763,072 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_312283010 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -228,934,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,725,178,380 |
| Number Of Analyst Opinions | 13 |
| Open | 115.07 |
| Operating Cashflow | -210,258,000 |
| Operating Margins | -38.50242 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 240 327 0630 |
| Previous Close | 115.0 |
| Price Eps Current Year | -27.412575 |
| Price Hint | 2 |
| Price To Book | 16.557732 |
| Price To Sales Trailing12 Months | 301.79318 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.322 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.010002136 |
| Regular Market Change Percent | 0.00869751 |
| Regular Market Day High | 115.07 |
| Regular Market Day Low | 115.005 |
| Regular Market Day Range | 115.005 - 115.07 |
| Regular Market Open | 115.07 |
| Regular Market Previous Close | 115.0 |
| Regular Market Price | 115.01 |
| Regular Market Time | 1,776,782,804 |
| Regular Market Volume | 377,628 |
| Return On Assets | -0.24052 |
| Return On Equity | -0.53418 |
| Revenue Growth | -0.892 |
| Revenue Per Share | 0.396 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 58,479,812 |
| Shares Percent Shares Out | 0.0388 |
| Shares Short | 2,269,775 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,763,954 |
| Short Name | Arcellx, Inc. |
| Short Percent Of Float | 0.052699998 |
| Short Ratio | 1.62 |
| Source Interval | 15 |
| State | CA |
| Symbol | ACLX |
| Target High Price | 120.0 |
| Target Low Price | 82.0 |
| Target Mean Price | 112.84615 |
| Target Median Price | 115.0 |
| Total Cash | 450,334,016 |
| Total Cash Per Share | 7.701 |
| Total Debt | 51,919,000 |
| Total Revenue | 22,286,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 82.297424 |
| Two Hundred Day Average Change | 32.712578 |
| Two Hundred Day Average Change Percent | 0.3974921 |
| Type Disp | Equity |
| Volume | 377,628 |
| Website | https://www.arcellx.com |
| Zip | 94,065 |